RxDoctor Payments Data

Shelley Rapach

Family · West Chester, OHNPI 1326540212

Payments from drug & device makers

$14,413in general payments, 2019–2025

Across 84 payments — averaging $171.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • Biohaven Pharmaceutical Holding Company Ltd.$4K
  • Pfizer$2K
  • Lundbeck LLC$306
  • Biohaven Pharmaceuticals, Inc.$125
  • Neurocrine Biosciences, Inc.$21

What the payments were for

  • Consulting fees$6755%
  • Speaking & faculty fees$11,48080%
  • Travel & lodging$2902%
  • Food & beverage$1,96814%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,413 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$18,325
Medicare patients
117
Services billed
246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant139$228,765
Nurtec OdtRimegepant Sulfate101$125,346
Aimovig AutoinjectorErenumab-Aooe120$93,745
Emgality PenGalcanezumab-Gnlm108$91,030
QuliptaAtogepant56$73,011
Ajovy AutoinjectorFremanezumab-Vfrm35$27,692
ReyvowLasmiditan Succinate17$16,244
Ajovy SyringeFremanezumab-Vfrm17$13,686
Memantine Hcl125$4,229
Sumatriptan Succinate86$4,184
Acetazolamide45$2,917
Topiramate152$2,079
Acetazolamide ErAcetazolamide28$2,030
Naratriptan Hcl27$1,528
Propranolol Hcl ErPropranolol Hcl19$1,359

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$7,759$301,776195 claims
PfizerNurtec Odt$2,312$125,346101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in West Chester

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →